Head, TCO (Translational Clinical Oncology) China

Provides strategic medical, clinical and scientific leadership of the TCO team in China, guiding program selection and execution of oncology early development portfolio in country in alignment with Global BR TCO and informing potential external innovative programs and business development in strategic oncology areas of focus for the company in China. May serve as a member of TCO LT.

Major Accountabilities Leads the BR TCO China organization in accordance with the global BR TCO clinical strategy, including its targeted build over time, providing strategic and operational steer.Oversees the selection and prioritization of compounds/modalities to be developed in China ensuring alignment with Global BR TCO, China Development and China Oncology Business Unit. Provides scientific and clinical input on internal and external assets and portfolio areas based on a deep understanding of local life sciences environment and TCO strategy:Represents TCO in Business Development and Licensing (BD&L) due diligence reviews and integrations, managing Novartis and external stakeholders in China.Develops relationships and partnerships in assessing external capabilities in early oncology and explores innovative drug development models in China to shorten the gap of registration timeline between China and global. Identifies opportunities for the introduction of new technologies and spearheads their introduction into TCO programs in China and globally.·       Leads or helps oversee external collaborations, partnering closely with global colleagues across the company.Drives China’s contribution to early oncology development globally through the strategic incorporation of regional and global elements key to Novartis success in China and Asia.Ensures TCO trials are being prepared and conducted scientifically, safely and successfully by ensuring adequate resourcing and support to the TCO China team  Interacts with the scientific and medical community to establish a qualified network of TCO first-in-human and proof-of-concept sites in China. Build and maintain collaborative relationships with PIs and KOLs who will be engaged long-term for advice and advocacy on the Novartis discovery and early development oncology pipeline in China.Represents Novartis early oncology in China in interactions with the regulatory agency NMPA, with HGRAC and with other authorities and decision-making bodies as appropriate.Provides local leadership for TCO associates and managers in China, guiding their development and engagementEnsures all activities of associates comply with Novartis China company standards and local regulations Ideal BackgroundEducation(minimum)MD degree and PhD-level basic science required (PhD not required). MD / PhD preferred. Board Certification (or equivalent expertise) in Hematology-Oncology (heme-onc).Oncology experience requiredPeople management experience required.Languages:Fluent Mandarin for verbal and written communication requiredFluent English for verbal and written communication required Experience/Professional requirement:Helps maintain and create a competitive edge and ensures that Novartis is seen as a credible, ethical, and preferred partner.·       Recognized as a Heme-Onc expert with a substantial record of quality scientific publications and international recognition for expertise.·       Interpretation of preclinical data in hematology/oncology (molecular biology, pharmacology, pharmacokinetics, and toxicology).·       Working knowledge of the application of Pharmacokinetics (PK) / Pharmacodynamics (PD) and biostatistics to clinical development and trials.·       Proven ability to analyze and interpret efficacy and safety data relating to oncology.Working knowledge of Good Clinical Practice and regulatory requirements relating to clinical trials and oncology.Proven ability to manage, develop and coach people.Strong interpersonal skills for bridging scientific, operational and business stakeholders.Experience working in a multicultural global organization.Excellent personal ethical integrity and a commitment to improving the outcomes for patients with malignancies.